Summary
Wy-13, 876, a hydroxythiazolobenzimidazole, enhanced in vitro antibody formation by mouse spleen cells immunized with sheep red blood cells. The optimal dose was 25–50 μg/culture. The compound did not have a mitogenic effect at any dose.
Similar content being viewed by others
References
J. Watson, E. Trenkner and M. Cohn, J. exp. Med.138, 699 (1973).
J. Andersson, J. Melchers, C. Galanos and O. Ludevitz, J. exp. Med.39, 943 (1973).
A. Coutinho and G. Möller, Scand. J. Immun.3, 133 (1974).
G. H. Warren, L. Mills and H. Friedman, J. reticuloendoth. Soc.20, 64A (1976).
R. L. Fenichel, F. J. Gregory and H. E. Alburn, Br. J. Cancer33, 329 (1976).
R. L. Fenichel, H. E. Album, W. E. Tucker, G. H. Warren and F. J. Gregory, Proc. 66th Meeting Am. Ass. Cancer Res., San Diego, California, May 1975.
I. Kamo, C. Patel, J. Kateley and H. Friedman, J. Immun.114, 1749 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Warren, G.H., Mills, L. & Friedman, H. Immunomodulating effects in vitro of a hydroxythiazolobenzimidazole in the absence of mitogenicity. Experientia 34, 802–803 (1978). https://doi.org/10.1007/BF01947337
Issue Date:
DOI: https://doi.org/10.1007/BF01947337